Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWATM204 in advanced hepatocellular carcinoma
NCT06144385Phase 1Recruiting
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JWATM204 in hepatocellular carcinoma (HCC), sponsored by Shanghai Ming Ju Biotechnology. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and Severe Adverse Events at 2 years and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
JWATM204
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06144385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144385.